Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sung Hoon Sim

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Breast Cancer Research and Treatment|May 30, 2020
Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patientsHyunsoon Cho, Sanghee Lee, Sung Hoon Sim, et al.
Journal of Cancer|April 21, 2018
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancerIn Hae Park, Sun-Young Kong, Youngmee Kwon, et al.
Journal of Breast Cancer|February 26, 2021
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerJee Hyun Kim, Seock Ah Im, Sung Hoon Sim, et al.
Journal of Cancer Research and Clinical Oncology|July 10, 2014
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancerSung Hoon Sim, Bhumsuk Keam, Dong-Wan Kim, et al.
Cancer Science|November 24, 2011
Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancerSung Hoon Sim, Yong-Oon Ahn, Jieun Yoon, et al.
Biology|November 13, 2020
The Tumor-Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant ChemotherapyHwan-Ho Cho, Minsu Park, Hyunjin Park, et al.
JMIR Public Health and Surveillance|March 8, 2023
Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World StudyDanbee Kang, Sooyeon Kim, Hyunsoo Kim, et al.
Thoracic Cancer|April 5, 2016
Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitorsSung Hoon Sim, Seung-Hoon Beom, Yong-Oon Ahn, et al.
Cancer Research and Treatment|September 3, 2016
A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as AnemiaDo Il Choi, Ho Seok Chi, Sang Ho Lee, et al.
Molecular Cancer Research : MCR|November 10, 2019
Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy ResponseJihyun Kim, Doyeong Yu, Youngmee Kwon, et al.
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Breast Cancer Research and Treatment|May 30, 2020
Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patientsHyunsoon Cho, Sanghee Lee, Sung Hoon Sim, et al.
Journal of Cancer|April 21, 2018
Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancerIn Hae Park, Sun-Young Kong, Youngmee Kwon, et al.
Journal of Breast Cancer|February 26, 2021
Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerJee Hyun Kim, Seock Ah Im, Sung Hoon Sim, et al.
Journal of Cancer Research and Clinical Oncology|July 10, 2014
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancerSung Hoon Sim, Bhumsuk Keam, Dong-Wan Kim, et al.
Cancer Science|November 24, 2011
Influence of chemotherapy on nitric oxide synthase, indole-amine-2,3-dioxygenase and CD124 expression in granulocytes and monocytes of non-small cell lung cancerSung Hoon Sim, Yong-Oon Ahn, Jieun Yoon, et al.
Biology|November 13, 2020
The Tumor-Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant ChemotherapyHwan-Ho Cho, Minsu Park, Hyunjin Park, et al.
JMIR Public Health and Surveillance|March 8, 2023
Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World StudyDanbee Kang, Sooyeon Kim, Hyunsoo Kim, et al.
Thoracic Cancer|April 5, 2016
Pretreatment neutrophil-lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor-mutant non-small cell lung cancer patients treated with tyrosine kinase inhibitorsSung Hoon Sim, Seung-Hoon Beom, Yong-Oon Ahn, et al.
Cancer Research and Treatment|September 3, 2016
A Rare Case of Phyllodes Tumor Metastasis to the Stomach Presenting as AnemiaDo Il Choi, Ho Seok Chi, Sang Ho Lee, et al.
Molecular Cancer Research : MCR|November 10, 2019
Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy ResponseJihyun Kim, Doyeong Yu, Youngmee Kwon, et al.
Pageof 8